Shorter hospitalization trends among children with sickle cell disease

Pediatric Blood and Cancer

Volumn 59, Issue 4, 2012, Pages 679-684

  Raphael, Jean L ^a   Mueller, Brigitta U ^a   Kowalkowski, Marc A ^a   Oyeku, Suzette O ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Health care utilization; Sickle cell disease

Indexed keywords

ADOLESCENT; ADOLESCENT HEALTH; ADULT; ARTICLE; BLOOD VESSEL OCCLUSION; CHILD; CHILD HEALTH; DATA BASE; FEMALE; GROUPS BY AGE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INFANT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SICKLE CELL ANEMIA;

ADOLESCENT; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; FEMALE; HOSPITALIZATION; HUMANS; INFANT; LENGTH OF STAY; MALE; VASCULAR DISEASES;

EID: 84864945603     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24065     Document Type: Article

References (40)

1. Yang YM, Shah AK, Watson M, et al. Comparison of costs to the health sector of comprehensive and episodic health care for sickle cell disease patients. Public Health Rep 1995; 110: 80-86.
2. Amendah DD, Mvundura M, Kavanagh PL, et al. Sickle cell disease-related pediatric medical expenditures in the U.S. Am J Prev Med 2010; 38: S550-S556.
3. Ballas SK. The cost of health care for patients with sickle cell disease. Am J Hematol 2009; 84: 320-322.
4. Carroll CP, Haywood C Jr, Fagan P, et al. The course and correlates of high hospital utilization in sickle cell disease: Evidence from a large, urban Medicaid managed care organization. Am J Hematol 2009; 84: 666-670.
5. Davis H, Moore RM Jr, Gergen PJ. Cost of hospitalizations associated with sickle cell disease in the United States. Public Health Rep 1997; 112: 40-43.
6. Raphael JL, Dietrich CL, Whitmire D, et al. Healthcare utilization and expenditures for low income children with sickle cell disease. Pediatr Blood Cancer 2009; 52: 263-267.
7. Raphael JL, Mei M, Mueller BU, et al. High resource hospitalizations among children with vaso-occlusive crises in sickle cell disease. Pediatr Blood Cancer (in press).
8. Mvundura M, Amendah D, Kavanagh PL, et al. Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States. Pediatr Blood Cancer 2009; 53: 642-646.
9. Kauf TL, Coates TD, Huazhi L, et al. The cost of health care for children and adults with sickle cell disease. Am J Hematol 2009; 84: 323-327.
10. Steiner CA, Miller JL. Sickle cell disease patients in U.S. hospitals; 2004; Report No.: HCUP statistical brief #21.
11. Powars DR, Hiti A, Ramicone E, et al. Outcome in hemoglobin SC disease: A four-decade observational study of clinical, hematologic, and genetic factors. Am J Hematol 2002; 70: 206-215.
12. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood 2004; 103: 4023-4027.
13. Quinn CT, Rogers ZR, McCavit TL, et al. Improved survival of children and adolescents with sickle cell disease. Blood 2010; 115: 3447-3452.
14. Lee A, Thomas P, Cupidore L, et al. Improved survival in homozygous sickle cell disease: Lessons from a cohort study. BMJ 1995; 311: 1600-1602.
15. Prabhakar H, Haywood C Jr, Molokie R. Sickle cell disease in the United States: Looking back and forward at 100 years of progress in management and survival. Am J Hematol 2010; 85: 346-353.
16. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986; 314: 1593-1599.
17. Vichinsky E, Hurst D, Earles A, et al. Newborn screening for sickle cell disease: Effect on mortality. Pediatrics 1988; 81: 749-755.
18. Vichinsky EP. Comprehensive care in sickle cell disease: Its impact on morbidity and mortality. Semin Hematol 1991; 28: 220-226.
19. McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: What have we learned and what questions still remain? Curr Opin Hematol 2011; 18: 158-165.
20. Shankar SM, Arbogast PG, Mitchel E, et al. Impact of proximity to comprehensive sickle cell center on utilization of healthcare services among children with sickle cell disease. Pediatr Blood Cancer 2008; 50: 66-71.
21. Raphael JL, Kavanagh PL, Wang CJ, et al. Translating scientific advances to improved outcomes for children with sickle cell disease: A timely opportunity. Pediatr Blood Cancer 2011; 56: 1005-1008.
22. Schwartz WB, Mendelson DN. Hospital cost containment in the1980s. Hard lessons learned and prospects for the 1990s. N Engl J Med 1991; 324: 1037-1042.
23. McCavit TL, Lin H, Zhang S, et al. Hospital volume, hospital teaching status, patient socioeconomic status, and outcomes in patients hospitalized with sickle cell disease. Am J Hematol 2011; 86: 377-380.
24. Brousseau DC, Owens PL, Mosso AL, et al. Acute care utilization and rehospitalizations for sickle cell disease. JAMA 2010; 303: 1288-1294.
25. Panepinto JA, Brousseau DC, Hillery CA, et al. Variation in hospitalizations and hospital length of stay in children with vaso-occlusive crises in sickle cell disease. Pediatr Blood Cancer 2005; 44: 182-186.
26. Ellison AM, Bauchner H. Socioeconomic status and length of hospital stay in children with vaso-occlusive crises of sickle cell disease. J Natl Med Assoc 2007; 99: 192-196.
27. Raphael JL, Kamdar A, Beavers MB, et al. Treatment of uncomplicated vaso-occlusive crises in children with sickle cell disease in a day hospital. Pediatr Blood Cancer 2008; 51: 82-85.
28. Raphael JL, Kamdar A, Wang T, et al. Day hospital versus inpatient management of uncomplicated vaso-occlusive crises in children with sickle cell disease. Pediatr Blood Cancer 2008; 51: 398-401.
29. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639-1644.
30. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet 2011; 377: 1663-1672.
31. Candrilli SD, O'Brien SH, Ware RE, et al. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol 2011; 86: 273-277.
32. Stallworth JR, Jerrell JM, Tripathi A. Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. Am J Hematol 2010; 85: 795-797.
33. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000; 342: 1855-1865.
34. Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr 2001; 139: 785-789.
35. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339: 5-11.
36. Drasar E, Igbineweka N, Vasavda N, et al. Blood transfusion usage among adults with sickle cell disease-A single institution experience over ten years. Br J Haematol 2011; 152: 766-770.
37. Nietert PJ, Abboud MR, Zoller JS, et al. Costs, charges, and reimbursements for persons with sickle cell disease. J Pediatr Hematol Oncol 1999; 21: 389-396.
38. Clarke A, Rosen R. Length of stay. How short should hospital care be? Eur J Public Health 2001; 11: 166-170.
39. Yusuf HR, Atrash HK, Grosse SD, et al. Emergency department visits made by patients with sickle cell disease: A descriptive study, 1999-2007. Am J Prev Med 2010; 38: S536-S541.
40. Grosse SD, Boulet SL, Amendah DD, et al. Administrative data sets and health services research on hemoglobinopathies: A review of the literature. Am J Prev Med 2010; 38: S557-S567.